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Abstract
Xanthelasma might be a clinical manifestation of dyslipidemia, a recognized risk factor for coronary artery disease.
We investigated the association of apolipoprotein E (APOE HhaI), apolipoprotein B (APOB XbaI and Ins/Del) and
LDL receptor (LDLR AvaII and HincII) gene polymorphisms with lipid profiles in 100 Brazilians with xanthelasma and
100 controls. Allele frequencies were similar in both groups. APOE, APOB and LDLR genotypes were not correlated
with differences in the serum lipid profile. In individuals with xanthelasma, the APOB D allele was associated with
less chance of having increased LDL-cholesterol (O.R. = 0.16, CI95% = 0.03-0.94, p = 0.042). In the control group,
the APOB X+ allele was associated with less chance of having both increased total cholesterol (O.R. = 0.16,
CI95% = 0.03-0.78, p = 0.023) and increased LDL-cholesterol (O.R. = 0.10, CI95% = 0.02-0.60, p = 0.012). More-
over, there was a significantly higher frequency of control individuals (68%) with elevated serum triglyceride levels,
compared to patients (48%, p = 0.008). On the other hand, triglyceride levels in controls also seemed to be influ-
enced by all other gene polymorphisms studied, an effect that might be enhanced by environmental factors.
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Introduction
Xanthelasma is the most common form of lipid de-
posit on the skin, and appears as yellowish plaques on the
eyelid or periorbital skin (Bergman, 1994). These have
been considered as clinicals sign of both dyslipidemia and
advanced atherosclerotic processes, implicated in the
pathogenesis of coronary artery disease (CAD) (Ribera et
al., 1995), although they have also been found in non-
dyslipidemicindividuals,therebysuggestingthatotherfac-
tors might be responsible for the formation of these athe-
rogenic manifestations (Tursen et al., 2006).
Variants in the genes encoding apolipoproteins E
(APOE)a n dB( APOB), as well as the low-density lipopro-
tein receptor (LDLR), have been associated with hypercho-
lesterolemia and the increased risk of CAD in several
populations(Hansenetal.,1993;Seriesetal.,1993;Ribera
et al., 1995; Salazar et al. 1999; 2000; Cavalli et al., 2000;
Pongrapeeporn et al., 2000; Guo et al., 2002; Hirashiki et
al., 2003; Rios et al., 2003; Souza et al., 2007). Xan-
thelasma in association with cardiovascular disease has
beenreportedinindividualswithfamilialhypercholesterol-
emia and carrying LDLR mutations (Norman et al., 1999),
and have also been associated with the presence of the
APOE*4 allele (Ribera et al., 1995).
With the aim of elucidating the contribution of com-
mon polymorphisms from those genes involved in lipid
metabolism to the development of xanthelasma, we evalu-
ated whether APOE (HhaI), APOB (XbaI and Ins/Del) and
LDLR (AvaII and HincII) gene polymorphisms were asso-
ciated with the lipid profile encountered in Brazilian indi-
viduals with xanthelasma.
Material and Methods
Subjects
We investigated 100 unrelated individuals of Euro-
pean descent from southeastern Brazil presenting xan-
thelasma (37 men and 63 women, between the ages of 32
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Research Articleand 60 years). They were selected by a medical dermatolo-
gist in a private dermatology clinic, during the period from
April, 2002 to March, 2005. Individuals with liver, renal or
thyroid diseases, hypertension, diabetes mellitus, family
dyslipidemia,andwhohadbeenusinglipid-loweringdrugs
during the prior six months, at least, were precluded. The
control group consisted of 100 individuals chosen from the
generalpopulation(36menand64women,agedfrom32to
57 years), and without any clinical signs of xanthomatosis
or any other lipoid metabolic disorder. This study was ap-
proved by the Ethics Research Committee of the Faculdade
de Medicina de São José do Rio Preto, SP, Brazil (protocol
2277/2002). Furthermore, all the participants signed infor-
mative forms, thereby indicating their consent.
Histopathology
The diagnosis of xanthelasma in all patients was con-
firmed through histopathological methods. Periorbital skin
lesions were surgically excised the tissues being immedi-
ately immersed in Carnoy’s methanolic fixative (60% me-
thanol, 30% chloroform, and 10% glacial acetic acid) con-
taining 25 moles/L of butylated hydroxytoluene and 50
pmoles/L of diethylenetriamine pentaacetic acid, to inhibit
anyexvivooxidativemodification.Thefixedsampleswere
embedded in paraffin according to Sugiyama et al. (1992).
Xanthelasma histological diagnosis was based on Breier et
al. (2002) criteria.
Serum lipid profile
The lipid profile in serum was determined from pe-
ripheral blood samples drawn after a 12 hours’ fast. The se-
rum concentrations of triglycerides (TG) and total choles-
terol(TC)weredefinedbyenzymaticcolorimetricmethods
(BucoloandDavid,1973;Allainetal.,1974).High-density
lipoprotein cholesterol (HDL-cholesterol) was determined
by precipitation with dextran-magnesium chloride. Low-
density lipoprotein (LDL-cholesterol) and very low-den-
sity lipoprotein cholesterol (VLDL-cholesterol) were cal-
culated by the Friedewald formula for TG levels below
400mg/dL(Friedewaldetal.,1972).TC/HDL-cholesterol,
LDL-cholesterol/HDL-cholesterol and TG/HDL-choles-
terolratioswerecalculated(DaLuzetal.,2005).Reference
valueswerethoserecommendedbytheIIIBrazilianGuide-
lines on Dyslipidemias and Guideline of Atherosclerosis
Prevention from Atherosclerosis Department of Sociedade
Brasileira de Cardiologia (Santos and Sociedade Brasileira
de Cardiologia, 2001).
Genomic DNA analysis
Genomic DNA was extracted from peripheral blood
leukocytes. APOE [APOE*2 (Cys176Arg, rs7412),
APOE*4 (Cys130Arg, rs429358)], APOB [XbaI
(Thr2515Thr, rs693)], LDLR [AvaII (Val653Val, rs5925)
andHincII(Asn591Asn,rs688)]genepolymorphismswere
analyzed through the polymerase chain reaction (PCR) and
restriction fragment length polymorphism (RFLP). The
APOB [Ins/Del (rs17240441)] variant was determined by
PCR. Amplification was carried out in an Eppendorf-
Mastercycler thermal cycler (Eppendorf HQ, Hamburg,
Germany). Primers and PCR conditions had been previ-
ously described (Hixson and Vernier, 1990; Renges et al.,
1991; Boerwinkle et al., 1990; Hobbs et al., 1992). PCR
products were analyzed by 1.5% agarose gel electrophore-
sis after ethidium bromide staining. These were then di-
gested with the endonucleases (Amersham Pharmacia
Biotech of Brazil) HhaI and XbaI for APOE and APOB sin-
gle nucleotide polymorphisms (SNPs), respectively, and
AvaII and HincII for LDLR SNPs, according to manufac-
turer’s instructions. Fragments were identified by electro-
phoresis on 2% agarose gels (APOB XbaI) and 6%
polyacrylamide gels (APOB Ins/Del, APOE HhaI, LDLR
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Table1-Demographic,biochemicalandgenotypicdataofBrazilianindi-
viduals with xanthelasma and controls.
Variables Individuals with
Xanthelasma
(n = 100)
Controls
(n = 100)
Pc
Age (years) 46.2  13.6 44.0  12.6 1.000
Gender (men, %) 37 36 1.000
Total cholesterol
(mg/dL)
203.6  26.9 206.1  32.7 1.000
HDL-c (mg/dL) 46.9  8.3 46.4  7.6 1.000
LDL-c (mg/dL) 126.3  26.3 126.3  35.6 1.000
VLDL-c (mg/dL) 30.0  8.4 32.7  6.6 0.080
Triglycerides (mg/dL) 149.8  41.8 163.4  33.0 0.080
TC/HDL-c 4.5  1.0 4.6  1.3 1.000
LDL-c/HDL-c 2.8  0.9 2.9  1.2 1.000
TG/HDL-c 3.3  1.2 3.6  1.0 0.640
APOE HhaI (%) (n = 50) (n = 89)
APOE*2 allele 7.0 4.0 1.000
APOE*3 allele 84.0 82.0
APOE*4 allele 9.0 14.0
APOB XbaI (%) (n = 99) (n = 100)
X+ allele 40.0 40.0 1.000
X- allele 60.0 60.0
APOB Ins/Del (%) (n = 99) (n = 100)
I allele 63.0 58.0 0.800
D allele 37.0 42.0
LDLR AvaII (%) (n = 50) (n = 50)
A+ allele 32.0 43.0 0.288
A- allele 68.0 57.0
LDLR HincII (%) (n = 86) (n = 100)
H+ allele 66.0 60.0 0.522
H- allele 34.0 40.0
n , number of individuals. TC, total cholesterol; HDL-c, high-density lipo-
protein cholesterol; LDL-c, low-density lipoprotein cholesterol; VLDL-c,
very low-density lipoprotein cholesterol; TG, triglycerides. +/-, presence/
absence of restriction site. Ins/Del, insertion/deletion. Continuous variable
data are reported as mean  SD and compared by the Mann-Whitney test.
Categorical variables were compared by chi-squared and the Fisher exact
tests. Pc = probability-value in reference to Bonferroni correction.AvaII and HincII). Homozygous samples for restriction
sites were used as positive control, and 10% of the analyses
were repeated randomly.
Statistical analysis
Categorical variables were compared by chi-squared
or Fisher Exact tests. Continuous variables were compared
through Mann-Whitney tests. Differences in genotype fre-
quencydistributionfromHardy-Weinbergratioswereveri-
fied by chi-squared tests. Genotype frequencies were esti-
mated by means of the Expectation-Maximization
algorithm using the Arlequin program. Relationships be-
tween xanthomatosis and genotypes and other variables
were evaluated by univariate logistic regression and multi-
variate logistic regression analyses with stepwise criteria.
The computer package SAS System 6.12 for Windows
(SAS Institute Inc., Cary, NC, USA) was used throughout
data analyses. Significance was defined as p < 0.05, after
application of the Bonferroni correction.
Results
Biopsyofperiorbitalskinlesionsfromallthepatients
showed a localized collection of histiocytes with a foamy
vacuolated cytoplasm, few lymphocytes and neutrophils in
the dermis, the absence of fibrosis, and the presence of gi-
ant Touton cells (data not shown).
Table 1 shows demographic, biochemical and geno-
typic data from the study and control groups. Tested vari-
ables revealed no diversity between individuals with
xanthelasma and controls. Allelic frequencies for APOE,
APOB and LDLR polymorphisms were similar in both
groups, and all the five polymorphisms exhibited the distri-
bution patterns predicted by Hardy-Weinberg equilibrium
(HWE), except APOB XbaI for patients (x
2
(1) = 3.97;
0 . 0 2<p<0.05).
No relationships were detected between gene poly-
morphismsandserumlipidsineitherofthetwogroups(Ta-
bles 2 and 3). In the control group, an increased
TG/HDL-cholesterol ratio was observed in LDLR H+H+
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Table 2 - Relationships between serum lipids and APOE, APOB and LDLR polymorphisms in individuals with xanthelasma. No statistically significant
differences were found.
Polymorphisms Lipids (mg/dL)
TC HDL-c LDL-c VLDL-c TG
APOE HhaI E2E3 (7) 204.9  40.2 46.3  6.1 131.7  42.4 26.9  4.0 134.3  19.5
E3E3 (34) 204.8  23.6 46.5  8.0 125.6  26.6 32.6  6.9 162.5  34.4
E3E4 (9) 204.1  14.0 47.7  10.1 122.9  13.6 33.6  7.2 167.4  36.2
P 0.422 0.893 0.801 0.073 0.069
Pc 1.000 1.000 1.000 0.219 0.207
APOB XbaI X+X+ (11) 208.0  22.4 49.1  7.8 126.4  22.0 32.5  6.4 162.6  32.2
X+X- (57) 203.0  25.4 47.5  7.5 126.3  24.5 28.9  8.7 144.1  43.3
X-X- (31) 203.8  31.6 45.4  9.5 126.6  31.4 31.2  8.4 155.5  41.9
P 0.759 0.343 0.915 0.079 0.071
Pc 1.000 1.000 1.000 0.237 0.213
APOB Ins/Del II (37) 206.1  32.2 47.3  9.7 128.1  30.8 28.7  7.8 143.1  38.8
ID (50) 202.3  23.4 46.1  7.2 125.7  23.5 31.2  9.1 155.4  45.5
DD (12) 203.3  24.6 49.7  7.5 124.3  24.9 29.3  6.9 146.3  35.1
P 0.702 0.461 0.820 0.398 0.432
Pc 1.000 1.000 1.000 1.000 1.000
LDLR AvaII A+A+ (3) 230.7  54.9 41.7  5.7 156.3  60.1 32.7  5.0 163.0  24.6
A+A- (26) 203.0  21.9 45.7  8.5 125.5  24.0 31.7  7.9 158.0  39.2
A-A- (21) 203.1  21.7 48.7  7.5 122.2  23.9 32.2  5.9 160.8  29.4
P 0.409 0.169 0.403 0.906 0.893
Pc 1.000 0.507 1.000 1.000 1.000
LDLR HincII H+H+ (35) 198.3  21.2 47.9  8.1 118.9  20.2 31.5  8.4 157.4  41.9
H+H- (43) 208.2  27.5 46.5  8.9 131.5  27.3 29.1  7.6 145.3  38.1
H-H- (8) 207.9  45.7 47.0  7.6 133.6  43.7 27.3  13.5 136.0  67.6
P 0.276 0.687 0.191 0.713 0.683
Pc 0.828 1.000 0.573 1.000 1.000
Number of individuals between parenthesis. TC, total cholesterol; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein choles-
terol;VLDL-c,verylow-densitylipoproteincholesterol;TG,triglycerides.+/-indicatesthepresence/absenceofarestrictionsite.Ins/Delindicatesinser-
tion/deletion.DataarereportedasmeanSDandcomparedbytheMann-Whitneytest.ValuesforAPOEgenotypeswerecomparedbytheKruskal-Wallis
test. Pc = probability-value in reference to Bonferroni correction.genotype carriers (p = 0.036) when compared to non-
carriers (data not shown).
Univariate logistic regression analysis showed that
individuals with xanthelasma stand less chance of having
increased TG (p = 0.014) and VLDL-cholesterol
(p = 0.014; Table 4), and that individuals with lower TG
(< 150 mg/dL) present an increased risk for xanthelasma
(O.R. = 2.30, CI95% = 1.30-4.09, p = 0.005) (data not
shown). Nevertheless, no relationships between gene poly-
morphisms and xanthelasma were found (Table 4).
Multivariate logistic regression analysis indicated
that the presence of APOB X+ allele was associated with
less chance of a rise in TC ( 200 mg/dL) (O.R. = 0.16,
CI95% = 0.03-0.78, p = 0.023) and LDL-cholesterol
(130mg/dL)(O.R.=0.10,CI95%=0.02-0.60,p=0.012)
in the control group (data not shown). On the other hand,
APOB D allele was associated with less chance of an in-
crease in LDL-cholesterol ( 130 mg/dL) (O.R. = 0.16,
CI95% = 0.03-0.94, p = 0.042) in individuals with xan-
thelasma (data not shown).
Discussion
In this study, the APOE, APOB and LDLR poly-
morphisms and serum levels of TC, HDL-cholesterol and
LDL-cholesterol were similarly distributed in individuals
with xanthelasma without co-morbidities and controls.
This reinforces the possibility of local lipid-profile alter-
ations with a deposit of lipids only at dermatological sites
(Bergman, 1994; Bergman et al., 1996).
Inourseries,theallelicandgenotypicdistributionsof
APOE HhaI polymorphism were similar in individuals
with xanthelasma and controls, and showed no significant
association to lipid profiles in either group. These results
aresimilartothosereportedbyGomezetal.(1988)andLin
et al. (2004). On the other hand, they differ from those by
Ribera et al. (1995), who detected a significantly increased
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Table 3 - Relationships between serum lipids and APOE, APOB and LDLR polymorphisms in the control group. No statistically significant differences
were found.
Polymorphisms Lipids (mg/dL)
TC HDL-c LDL-c VLDL-c TG
APOE HhaI E2E3 (4) 186.5  9.8 44.3  4.6 108.3  16.4 34.0  2.7 169.3  13.3
E3E3 (63) 206.5  32.7 47.3  7.5 126.2  35.4 33.0  6.6 164.7  33.1
E3E4 (16) 213.3  36.3 45.8  8.0 132.3  39.5 35.1  5.5 175.4  27.4
P 0.261 0.628 0.543 0.142 0.160
Pc 0.783 1.000 1.000 0.426 0.480
APOB XbaI X+X+ (12) 206.3  36.1 48.4  6.8 122.8  27.5 35.0  11.4 174.2  56.6
X+X- (56) 201.9  30.1 47.2  7.7 121.3  35.1 32.2  5.8 160.6  29.1
X-X- (32) 213.4  35.6 44.2  7.4 136.3  38.1 32.9  5.6 164.1  28.1
P 0.226 0.152 0.159 0.897 0.924
Pc 0.678 0.456 0.477 1.000 1.000
APOB Ins/Del II (30) 210.0  39.6 45.1  7.6 130.3  45.4 32.1  7.1 160.3  36.0
ID (56) 206.8  31.9 47.0  7.5 126.1  33.2 33.7  6.6 167.9  32.7
DD (14) 195.1  13.7 46.6  8.3 118.1  17.3 30.4  4.9 151.9  25.2
P 0.769 0.614 0.851 0.260 0.300
Pc 1.000 1.000 1.000 0.780 0.900
LDLR AvaII A+A+ (9) 209.9  29.2 46.6  6.2 131.2  36.0 32.1  3.4 159.9  17.4
A+A- (25) 211.2  38.6 48.0  7.5 129.2  40.0 34.0  8.9 169.8  44.0
A-A- (16) 203.3  22.6 45.7  6.9 122.9  25.6 34.6  5.6 173.1  28.4
P 0.960 0.499 0.943 0.556 0.540
Pc 1.000 1.000 1.000 1.000 1.000
LDLR HincII H+H+ (32) 200.9  27.5 44.3  7.2 120.3  33.8 33.8  5.9 168.8  29.8
H+H- (55) 203.6  31.3 47.9  7.8 124.0  31.9 32.1  7.3 160.2  36.2
H-H- (13) 229.4  42.4 45.2  7.1 150.3  47.0 32.7  5.1 163.6  26.2
P 0.095 0.102 0.119 0.265 0.259
Pc 0.285 0.306 0.357 0.795 0.777
Number of individuals between parentheses. TC, total cholesterol; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein choles-
terol;VLDL-c,verylow-densitylipoproteincholesterol;TG,triglycerides.+/-indicatesthepresence/absenceofarestrictionsite.Ins/Delindicatesinser-
tion/deletion.DataarereportedasmeanSDandcomparedbytheMann-Whitneytest.ValuesforAPOEgenotypeswerecomparedbytheKruskal-Wallis
test. Pc, probabilities in reference to the Bonferroni correction.frequency of the E3E4 genotype in patients with xantho-
matosistogetherwithanalteredlipidprofile.Moreover,the
presence of the APOE*2 allele was shown to be a factor re-
lated to significantly higher levels of TG and lower levels
of TC and LDL-cholesterol in control individuals com-
pared to patients (Eto et al., 1986). This intensifies contro-
versy regarding the protective effect against cardiovascular
manifestations conferred by this allele (Yang et al., 2004).
This study showed similarities between the groups
when considering allelic frequencies and genotypic combi-
nations of APOB XbaI and Ins/Del gene polymorphisms.
The genotypic distribution observed for APOB XbaI was
found to be just marginally different (p = 0.02-0.05) from
that expected within the HWE hypothesis in the group of
patients.
Multivariate logistic regression analysis with step-
wise criteria revealed an association between the presence
of the APOB X+ allele and less chance of an increase in TC
and LDL-cholesterol in the control group, this being con-
trary to results as reported by Series et al. (1993).
Brazilian individuals with xanthelasma, and who
werecarriersoftheAPOBDallele,presentedlesschanceof
undergoinganincreaseinLDL-cholesterol,thissuggesting
its association with the lipid profile, as already reported by
Hansenetal.(1993)inDenmark.However,noassociations
were detected through other studies (Gaffney et al., 1993;
Jemaa et al. 2004).
LDLR AvaII and HincII polymorphisms did not dis-
criminate groups by their allelic or genotypic distribution,
nordidtheyexertanyinfluenceonthelipidprofile.Contro-
versial results were reported in Thai subjects by Pongra-
peeporn et al. (2000), when considering the presence of the
A+A+genotypeassociatedtohigherTCandTG,andlower
HDL-cholesterol levels. Additionally, Salazar et al. (1999)
demonstrated increased TC and LDL-cholesterol levels in
Brazilian carriers of the H+H+ genotype.
In conclusion, our data show that apoE, apoB and
LDLR polymorphisms are not associated with a predisposi-
tion for xanthelasma. However, distinct APOB polymor-
phisms are highlighted as risk factors for alterations of the
lipidprofileinindividualswithxanthelasma(APOBD)and
controls (APOB X+).
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